Why early-stage businesses should validate the few commercial assumptions that matter most before investing heavily in sales and marketing
Early-stage businesses are often encouraged to move quickly towards market.
Build the website. Start outreach. Hire sales. Find partners. Generate demand.
But there is a question that should come first:
What actually needs to be true for the commercial model to work?
This is particularly important for early-stage science, technology and other complex businesses where the product may be credible, interest may already exist and early conversations may be encouraging, but the route to market is still uncertain.
You may not yet know who values the proposition most strongly, who makes the buying decision, who pays, what evidence they need, or which route provides repeatable access to the market.
Until those assumptions have been tested, investing more heavily in sales and marketing can simply scale uncertainty.
Start with the assumptions that matter most
Most early-stage businesses have dozens of unanswered questions.
The challenge is not to answer all of them at once.
It is to identify the handful of assumptions that carry the greatest commercial risk.
For example:
- Are we targeting the right first market?
- Does the problem matter enough for someone to act?
- Is the proposition sufficiently compelling?
- Who is actually prepared to pay?
- Is the expected price credible?
- Can we reach the target audience efficiently?
- Does the commercial model work at a realistic level of adoption?
If one of those assumptions proves wrong, it may materially change the route forward.
That is why commercial validation should not be about proving that the original idea is right.
It should be about identifying where it could be wrong before significant time and capital are committed.
Separate the user, influencer, buyer and payer
One of the most useful exercises for an early-stage business is to map the different people involved in the commercial decision.
In a simple transaction, the person using the product may also be the person buying and paying for it.
In more complex markets, particularly life sciences, healthcare, education and enterprise technology, those roles can be very different.
There may be:
The user
The person who ultimately experiences the value.
The influencer
Someone whose recommendation or support affects the decision.
The buyer
The person or organisation making the purchasing decision.
The payer
The individual or organisation funding it.
Sometimes these roles overlap. Often they do not.
That distinction matters because each audience may need a different reason to engage.
A scientist may care about technical credibility.
A commercial partner may care about strategic fit and future value.
An investor may care about market potential, milestones and risk.
A customer may care about solving an immediate operational problem.
The underlying proposition should remain consistent, but the emphasis and proof points need to reflect what matters to each audience.
A useful question is:
What does each stakeholder need to believe before the commercial decision can move forward?
Interest is useful evidence. It is not validation.
One of the easiest traps for early-stage companies is to confuse positive feedback with commercial validation.
People may say:
“This is really interesting.”
“I can see the value.”
“We should keep talking.”
“I would probably buy something like this.”
All of those responses are useful.
But they are not the same as someone making a real decision.
There is an important difference between:
Interest → stated intent → commitment → payment → repeatable behaviour
The further you move along that sequence, the stronger the evidence becomes.
A founder may have one paying customer and still not have a repeatable commercial model.
Equally, a business may conduct ten positive interviews without establishing whether people will actually spend money.
That does not make qualitative research unhelpful.
Quite the opposite.
Customer and stakeholder conversations are extremely useful for understanding:
- Perceived value
- Motivations
- Objections
- Decision criteria
- Willingness to consider the proposition
- Barriers to adoption
- Language and messaging
But they should be treated as one stage in the evidence-building process.
Where possible, they should lead to a more meaningful real-world test.
Compare routes to market rather than assuming the answer
Early-stage businesses often have several plausible routes to market.
A company might consider:
- Direct sales
- Strategic partnerships
- Distributors
- Licensing
- Channel partners
- Sponsorship
- Public-sector routes
- Direct-to-customer acquisition
The temptation is to choose the route that feels most familiar or accessible.
A better approach is to compare the credible options against a consistent set of criteria.
For example:
Demand
Is there evidence that the audience genuinely values the proposition?
Buyer and payer clarity
Do we understand who makes the decision and who funds it?
Access
Can we reach the audience efficiently?
Willingness to pay
Is there evidence that the value supports the likely price?
Commercial viability
Do the economics work?
Repeatability
Can the route be turned into a repeatable process?
Founder dependency
Does every opportunity currently depend on the founder's personal relationships?
Remaining uncertainty
How much still needs to be proven?
This makes the route-to-market decision much more disciplined.
The objective is not necessarily to identify the perfect route immediately.
It is to decide which route deserves the next investment of time and money.
Define what evidence would change the decision
Testing becomes much more useful when the decision criteria are agreed in advance.
Rather than saying:
“Let's see whether this market is interested.”
Ask:
“What would we need to observe to invest further, and what would cause us to change direction?”
That might include:
- A particular type of stakeholder agreeing to a next step
- A minimum level of conversion
- Evidence that a proposition resonates with one audience more strongly than another
- Acceptable customer acquisition economics
- A pricing response that supports the model
- Evidence that a route can work without relying entirely on founder relationships
The exact thresholds will vary.
The principle is more important.
Define, before the test, what evidence would:
Support the hypothesis
Weaken the hypothesis
Cause you to reject or rethink it
This reduces the risk of interpreting every result as confirmation of what you already hoped to be true.
There is also an important distinction between qualitative and behavioural evidence.
A small number of stakeholder interviews should not be given artificial pass or fail thresholds.
Their purpose is to uncover patterns, understand motivations and improve the next test.
The stronger decision thresholds should usually sit around real-world behaviour.
Validation should lead to a decision
Commercial validation can easily become another research exercise.
That is not the objective.
The aim is to reduce uncertainty enough to make the next commercial decision with greater confidence.
At the end of a focused validation process, a founder should have a clearer view of:
- Which audience deserves priority
- What proposition is most likely to make them act
- Who influences, buys and pays
- Which route to market is most credible
- Which assumptions remain unproven
- What should be tested next
- Where further investment is justified
That is very different from trying to create a complete GTM strategy before the evidence exists.
In many cases, the better sequence is:
Understand → Validate → Decide → Activate
Not:
Plan everything → Launch everything → Hope the assumptions were right
Clarity before scale
For early-stage businesses, speed matters.
But speed is not the same as rushing into execution.
The fastest route to commercial progress is often to spend a short period identifying and testing the assumptions that could otherwise consume months of sales and marketing effort.
Before investing significantly in campaigns, technology, sales resource or commercial infrastructure, ask:
What do we still need to believe for this route to market to work?
Which of those assumptions carries the greatest commercial risk?
What is the fastest credible way to test it?
What evidence would cause us to change direction?
Then build the go-to-market plan.
Not the other way around.